An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia

Inclusion Criteria: * Has stable schizophrenia or schizoaffective disorder * Has demonstrated ability to tolerate aripiprazole * Has been on a stable antipsychotic medication regimen without any changes for at least 2 months prior to screening * Has a body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive * Additional criteria may apply Exclusion Criteria: * Is pregnant, breastfeeding, or is planning to become pregnant during the study period * Has received aripiprazole lauroxil or IM depot aripiprazole within 6 months, or other long-acting, injectable antipsychotic medication within 3 months * Is a danger to himself/herself at screening or upon admission * Has a history of or positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C * Has a positive urine drug screen at screening or Day 1 * Additional criteria may apply